Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + Trastuzumab + SHR6390 + Letrozole for neoadjuvant treatment of stage II–III triple-positive breast cancer
ChiCTR2200055628Phase 2Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib, trastuzumab, dalpiciclib and letrozole in breast cancer, sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Total pathological complete response (tpCR). Started Feb 2022; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200055628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055628.